GET DAILY SIGNALSMDxHealth (MDXH): Assessing the Path to a +400% Gain Toward $0.75
Key Takeaways
- The central $0.75 stock price target is the arithmetic mean of the two verified, current analyst price targets we identified — $0.50 from Lake Street and $1.00 from TD Cowen — not a published consensus figure.
- With the stock trading around $0.15 (roughly $0.146), reaching $0.75 would require an increase of roughly 400%, an extremely large move even for a small-cap diagnostics name.
- Only a narrow set of targets remains active; the two analyst targets span a wide $0.50 to $1.00 range, reflecting genuine disagreement about MDxHealth's execution and liquidity.
- Recent sentiment has deteriorated sharply: BTIG, Craig-Hallum, and Lake Street all cut MDxHealth to neutral ratings in mid-October 2026 after a preliminary Q3 revenue miss and the suspension of 2026 guidance.
- Key supports include a focused prostate-cancer diagnostics franchise and growing liquid-based (Exo mdx) volumes; the biggest risks are sales-force turnover, a Medicare recoupment dispute, and Nasdaq listing-compliance pressure.
- Readers can explore more on Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For automated, AI-driven trade ideas across thousands of stocks and ETFs, explore Trending AI Robots.
Understanding the Current Analyst Targets
MDxHealth (MDXH), officially MDxHealth SA, is a Belgium-headquartered precision-diagnostics company focused on urology and prostate cancer. It is a stock, not an exchange-traded fund. Coverage of MDXH has thinned as the shares collapsed from a 52-week high near $4.35 to penny-stock territory, and only two attributable, current price targets remain.
Daniel Brennan of TD Cowen reiterated a Buy rating with a $1.00 target in August 2026, while Thomas Flaten of Lake Street cut his target to $0.50 from $3 and downgraded the shares to Hold on October 16, 2026. The arithmetic mean of these two targets is $0.75, which we use as the central target. The range is wide — $0.50 to $1.00 — and neither figure represents an official consensus; the average analyst price target of $0.75 is our own calculation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The October downgrades from BTIG, Craig-Hallum, and Lake Street were driven by a preliminary Q3 2026 revenue shortfall, sales-force turnover after the Resolve mdx wind-down, the suspension of 2026 revenue guidance, and renewed liquidity questions. TD Cowen's more bullish $1.00 view reflects longer-term confidence in the prostate-cancer franchise and upcoming clinical readouts.
Current Market Position and Path Toward the Target
MDXH trades around $0.15, down roughly 96% over the past year, with a market capitalization near $14 million. Reaching the $0.75 central target would require an approximately 400% gain, which is a very large move by any standard. The path would effectively require the company to restore credibility on execution and financing, because the stock now trades well below the $1.00 minimum bid price that Nasdaq generally requires for continued listing.
The fundamentals paint a strained picture. Third-quarter 2026 preliminary revenue from continuing operations was about $22.7 million, roughly flat year over year, and management suspended its full-year 2026 guidance of $110–115 million. The nine-month operating loss widened to about $21.4 million from $10.6 million a year earlier. Cash stood near $31.7 million at September 30, 2026, giving some runway but not removing liquidity concerns.
What Could Support a Move Toward the Target
A durable recovery would likely hinge on stabilization of the sales force and a return to revenue growth. The company's tissue-based Confirm mdx and GPS mdx (Genomic Prostate Score) tests and liquid-based Exo mdx test give it a focused, pure-play position in prostate-cancer diagnostics. Liquid-based Exo mdx volumes more than doubled year over year in Q3, a genuine bright spot. Clinical catalysts — including the PROMPT publication and an anticipated PROTECT readout — could refocus investor attention on the product story, and management has said it expects to return to growth in its end markets.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Sales-force turnover after discontinuing Resolve mdx disrupted a forecast process that had been reliable for three years, and tissue-based test volume fell 11% year over year in Q3. A $10.4 million Medicare recoupment notice tied to the discontinued Resolve UTI business adds financial uncertainty. The company has flagged Nasdaq compliance deficiencies around both the minimum bid price and the Market Value of Listed Securities (MVLS) requirement, and recent equity offerings have diluted existing shareholders. Continued losses, potential further dilution, and a failure to restore growth visibility could keep the shares depressed.
Technical Levels and Market Structure
The stock sits near the bottom of its 52-week range of roughly $0.14 to $4.35, with little durable support below the current price. The $1.00 level is psychologically significant because it coincides with Nasdaq's minimum bid-price threshold and with TD Cowen's target. The 200-day moving average remains far above the current price, reflecting a deep, intact downtrend, so any move toward $0.75 would first require reclaiming lower, currently broken levels.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may differ and MDxHealth's targets carry unusual uncertainty given the suspended guidance. Investors should watch the full third-quarter results and earnings call, any update on the Medicare recoupment dispute, progress toward Nasdaq compliance, changes to analyst ratings and targets, and clinical-readout timing for the PROTECT study.
Using Tickeron AI Tools in My Process
In my research, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts across volatile names like this one. The platform applies artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a low-priced stock such as MDXH, these signals can help identify trend changes more efficiently than manual review alone. Traders can use them to spot opportunities, track positions, and respond to evolving market structure. I find this approach particularly helpful when guidance is suspended and analyst views diverge sharply.
Final Assessment
Can MDxHealth reach $0.75? The central target is the mean of two current analyst targets — $0.50 and $1.00 — and sits roughly 400% above the current price, a very large required move. The bull case rests on a focused prostate-cancer franchise, growing Exo mdx volumes, and potential clinical catalysts, while the bear case rests on a revenue miss, suspended guidance, sales-force disruption, the Medicare recoupment, and listing-compliance risk. The wide $0.50-to-$1.00 range and the wave of downgrades show that even the covering analysts disagree sharply on the near-term outlook. Whether the target is reachable depends on execution and financing stability that have yet to be demonstrated, and no outcome is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXH's RSI Indicator stays in oversold zone for 18 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MDXH just turned positive on November 06, 2026. Looking at past instances where MDXH's MACD turned positive, the stock continued to rise in 24 of 30 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 96 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 37 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MDXH entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (67.298). P/E Ratio (0.000) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement